Physician profile
Wonchon Lin
NPI 1417214313
$42,712.48
in general payments reported to CMS, 2019-2025
20 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $131 · 2021: $21.70 · 2022: $16K · 2023: $26K · 2024: $149 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,090.00 |
| Food and Beverage | $556.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $41,660.00 | 2022-2023 | Hillrom - Retinavue Network, Hillrom - Retinavue 700 Imager |
| Tarsus Pharmaceuticals, INC. | $178.30 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $164.07 | 2023-2025 | Cequa, Xelpros |
| Ivantis, INC | $150.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $120.82 | 2019 | |
| Alcon Vision LLC | $56.24 | 2022-2025 | Tryptyr |
| Ocular Therapeutix, INC. | $51.58 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $49.65 | 2024 | Miebo, Xiidra |
| New World Medical,INC. | $46.00 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $32.25 | 2019-2020 | |
| Oyster Point Pharma, INC. | $30.82 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $29.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.96 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.99 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.98 | 2023 | |
| Rxsight INC | $17.09 | 2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Harrow Eye, LLC | $16.68 | 2025 | Vevye |
| Biotissue Holdings INC. | $15.82 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonchon Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.